Liquid biopsy is an advanced non-invasive cancer diagnostic technique that uses bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine for detecting cancer. Liquid biopsy uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers for diagnosis of cancer. Increasing demand for non-invasive diagnostic procedures is expected to boost growth of the global liquid biopsy market over the forecast period. Furthermore, increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global Liquid Biopsy and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global Liquid Biopsy based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global Liquid Biopsy report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Liquid Biopsy Market, By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- Liquid Biopsy Market, By Sample Type:
- Liquid Biopsy Market, By Disease Indication:
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- Liquid Biopsy Market, By End User:
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- Liquid Biopsy Market, By Region:
- North America
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- Latin America
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Biocept, Inc. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Qiagen N.V
- Trovagene, Inc.
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc.
- F. Hoffmann-La Roche Ltd.
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
“*” marked represents similar segmentation in other categories in the respective section.
